Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma (PSMA，ASL，PET)

September 13, 2024 updated by: Jing Zhang, The Second Hospital of Lanzhou University

Similarity of Biological Information Captured by (68)Gallium-prostate Specific Membrane Antigen-11 Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma

Evaluating the relationship between prostate-specific membrane antigen positron emission tomography and arterial spin labeling perfusion imaging, and the correlation with prostate-specific membrane antigen expressed on glioblastoma microvascular.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

26

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Gansu
      • Lanzhou, Gansu, China, 730000
        • The Second Hospital of Lanzhou University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Twenty-six patients with newly diagnosed or recurrent glioblastoma who underwent conventional MRI, ASL and PSMA PET were prospectively enrolled

Description

Inclusion Criteria:

  • Newly diagnosed or recurrent glioblastoma;
  • Adult (≥18 years old);

Exclusion Criteria:

  • The patient has a serious underlying disease or mental illness and is unable to cooperate with the imaging examination;
  • Have received systematic chemotherapy;
  • The image data is of poor or incomplete quality;
  • pregnant women;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Correlation between PSMA PET and ASL
The relationship between multimodal images
Diagnostic test: glioblastoma
All patients underwent conventional MRI, ASL perfusion imaging and 68Ga-PSMA-11 PET/CT examinations within 1 week interval

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The similarity of biological information
Time Frame: 2 week
Evaluating the similarity of biological information captured by prostate-specific membrane antigen positron emission tomography and arterial spin labeling perfusion imaging in glioblastoma.
2 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Second Hospital of Lanzhou University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2022

Primary Completion (Actual)

February 29, 2024

Study Completion (Actual)

February 29, 2024

Study Registration Dates

First Submitted

September 4, 2024

First Submitted That Met QC Criteria

September 13, 2024

First Posted (Estimated)

September 19, 2024

Study Record Updates

Last Update Posted (Estimated)

September 19, 2024

Last Update Submitted That Met QC Criteria

September 13, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • JZhang-1990
  • 23JRRA1625 (Other Grant/Funding Number: the Natural Science Foundation of Gansu Province)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glioblastoma

Clinical Trials on glioblastoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe